ASX:MEM Memphasys (MEM) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MEM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume246,322 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.20%Price TargetN/A Stock AnalysisStock Analysis Get Memphasys alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Memphasys Stock (ASX:MEM)Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… MEM Stock News HeadlinesMay 22, 2023 | hk.finance.yahoo.comMemphasys Reaches AU$20m Market Cap Benefiting Insider Stock BuyingMay 20, 2023 | finance.yahoo.comMemphasys Reaches AU$20m Market Cap Benefiting Insider Stock Buying \April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2023 | afr.comBlood pressure rises at Aegros, the next plasma hopefulApril 2, 2023 | msn.comDr Boreham’s Crucible: Every sperm is sacred – and profitableMarch 9, 2023 | finance.yahoo.comMemphasys Limited (IG7.F)February 25, 2023 | finance.yahoo.comMemphasys First Half 2023 Earnings: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2022)February 23, 2023 | marketwatch.comResearch Insight View on Centrifugation-free Sperm Separation Systems Market Size [2023-2028] | Emerging Trend and Current DevelopmentsApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 6, 2023 | msn.comASX Health Stocks: Creso eyes psychedelic spinout off the back of landmark TGA decisionDecember 11, 2022 | finance.yahoo.comA Memphasys Limited (ASX:MEM) insider increased their holdings by 6.2% last yearJuly 27, 2022 | afr.comPlacement outbreak: Creso Pharma, New World, Memphasys chase investorsJune 9, 2022 | msn.comASX Health Stocks: Neurotech says its cannabis strain works well when combined with DiclofenacMarch 20, 2022 | proactiveinvestors.com.auMemphasys achieves quality certification for medical devices and diagnosticsJanuary 26, 2022 | proactiveinvestors.com.auMemphasys outlines vision for biological separation tech in 2022December 8, 2021 | msn.comStandouts: 3 ASX biotech shares that outperformed in NovemberDecember 7, 2021 | au.finance.yahoo.comMemphasys Limited (MEM.AX)November 16, 2021 | msn.comThese 3 ASX healthcare shares are soaring today. Why?November 2, 2021 | msn.comASX Health Stocks: Paradigm rockets 21pc after getting FDA nod, Memphasys up 31pc on imminent launchJuly 29, 2021 | fool.com.auEllume is making news and these ASX shares are surging, againJuly 28, 2021 | msn.comWhen Ellume is making news, these ASX shares are in focusSee More Headlines Receive MEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Memphasys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:MEM CUSIPN/A CIKN/A Webwww.memphasys.com Phone61 2 8415 7300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.98% Return on Assets-16.93% Debt Debt-to-Equity Ratio83.82 Current Ratio0.17 Quick Ratio0.39 Sales & Book Value Annual Sales$81,148.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.20 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares1,370,000,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.72 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. David AliActing CEO & Executive DirectorPablo NeyertzDirector of FinanceAssociate Prof. Hassan BakosDirector of OperationsProf. R. John Aitken Ph.D.ScD FRSE, Scientific DirectorMr. Andrew Metcalfe B.BusCPA, FGIA, MAICD, Company SecretaryKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors This page (ASX:MEM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe World's First "$20 Trillion Drug?"Behind the MarketsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Memphasys Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
